Cox, Robert M. http://orcid.org/0000-0003-0620-1674
Wolf, Josef D. http://orcid.org/0000-0003-2507-6944
Lieberman, Nicole A. http://orcid.org/0000-0001-9334-8150
Lieber, Carolin M.
Kang, Hae-Ji
Sticher, Zachary M. http://orcid.org/0000-0002-7022-1410
Yoon, Jeong-Joong http://orcid.org/0000-0001-9379-0416
Andrews, Meghan K. http://orcid.org/0000-0001-8491-3824
Govindarajan, Mugunthan
Krueger, Rebecca E. http://orcid.org/0000-0003-1962-7578
Sobolik, Elizabeth B. http://orcid.org/0000-0003-3539-0718
Natchus, Michael G.
Gewirtz, Andrew T.
deSwart, Rik L. http://orcid.org/0000-0003-3599-8969
Kolykhalov, Alexander A.
Hekmatyar, Khan
Sakamoto, Kaori
Greninger, Alexander L. http://orcid.org/0000-0002-7443-0527
Plemper, Richard K. http://orcid.org/0000-0003-2034-2107
Funding for this research was provided by:
U.S. Department of Health & Human Services | NIH | National Institute of Allergy and Infectious Diseases (AI071002, AI171403, AI171403)
Article History
Received: 3 November 2023
Accepted: 23 January 2024
First Online: 8 February 2024
Competing interests
: R.K.P. and R.M.C. are co-inventors on a patent filing covering method of use of GHP-88309 for antiviral therapy. This study could affect their personal financial status. R.K.P. reports contract testing from Enanta Pharmaceuticals and Atea Pharmaceuticals, and research support from Gilead Sciences, outside of the described work. R.M.C. reports consulting for Merck & Co., outside of the described work. A.L.G. reports contract testing from Abbott, Cepheid, Novavax, Pfizer, Janssen and Hologic and research support from Gilead Sciences, outside of the described work. R.L.d.S. reports research support from Gilead Sciences and Themis Biosciences, outside of the described work. All other authors declare that they have no competing interests to report.